X0202 SCHEDULE 13G/A 0001712417 XXXXXXXX LIVE 3 COMMON STOCK, $0.0001 PAR VALUE PER SHARE 03/31/2026 0001863127 Tyra Biosciences, Inc. 90240B106 2656 State Street Carlsbad CA 92008 Rule 13d-1(d) Canaan XI L.P. b E9 750000.00 0 750000.00 0 750000.00 N 1.4 PN Based on 53,867,115 shares of Common Stock outstanding as of February 25, 2026, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2026. Canaan Partners XI LLC b DE 750000.00 0 750000.00 0 750000.00 N 1.4 OO Based on 53,867,115 shares of Common Stock outstanding as of February 25, 2026, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2026. Canaan 2020+ Co-Investment L.P. - Series 7 b DE 0.00 0 0.00 0 0.00 N 0.0 PN Canaan Partners 2020+ Co-Investment LLC b DE 0.00 0 0.00 0 0.00 N 0.0 OO Tyra Biosciences, Inc. 2656 State Street, Carlsbad, CA 92008 (i) Canaan XI L.P., a Cayman Islands limited partnership ( "Canaan XI"); (ii) Canaan Partners XI LLC, a Delaware limited liability company ("Canaan XI GP"); (iii) Canaan 2020+ Co-Investment L.P. - Series 7, a Delaware limited partnership ("Canaan Series 7"); and (iv) Canaan Partners 2020+ Co-Investment, LLC, a Delaware limited liability company ("Canaan 2020+ GP"). The address of the principal business office of each of the Reporting Persons is 855 Oak Grove, Suite 201, Menlo Park, California 94025. See Item 2(a) above. Y (i) Canaan XI directly owns 750,000 shares of Common Stock, which represents approximately 1.4% of the outstanding shares of Common Stock. (ii) Canaan XI GP is the general partner of Canaan XI and may be deemed to beneficially own 750,000 shares of Common Stock, which represents approximately 1.4% of the outstanding shares of Common Stock. (iii) Canaan Series 7 no longer beneficially owns any shares of Common Stock as of March 31, 2026. (iv) Canaan 2020+ GP is the general partner of Canaan Series 7 and no longer beneficially owns any shares of Common Stock as of March 31, 2026. The percent of class of the outstanding shares of Common Stock beneficially owned by the Reporting Persons in Item 4(a) are based on 53,867,115 shares of Common Stock outstanding as of February 25, 2026, as disclosed in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2026. (1) Canaan XI: 750,000 shares of Common Stock; (2) Canaan XI GP: 750,000 shares of Common Stock; (3) Canaan Series 7: 0 shares of Common Stock; and (4) Canaan 2020+ GP: 0 shares of Common Stock. None. (1) Canaan XI: 750,000 shares of Common Stock; (2) Canaan XI GP: 750,000 shares of Common Stock; (3) Canaan Series 7: 0 shares of Common Stock; and (4) Canaan 2020+ GP: 0 shares of Common Stock. None. N Y Y Y Y Y Y Canaan XI L.P. /s/ Nancy Levenson 04/24/2026 Canaan Partners XI LLC /s/ Nancy Levenson 04/24/2026 Canaan 2020+ Co-Investment L.P. - Series 7 /s/ Nancy Levenson 04/24/2026 Canaan Partners 2020+ Co-Investment LLC /s/ Nancy Levenson 04/24/2026